73.12 
0.17(0.23%) 04:02 SGT
| Prev Close: | 73.29 |
|---|
| Open: | 72.83 |
|---|
| Bid: | 72.10 x 200 |
|---|
| Ask: | 74.27 x 200 |
|---|
| 1y Target Est: | 75.34 |
|---|
| Beta: | 0.42 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 72.80 - 73.29 |
|---|
| 52wk Range: | 53.88 - 75.73 |
|---|
| Volume: | 879,014 |
|---|
| Avg Vol (3m): | 1,515,220 |
|---|
| Market Cap: | 179.67B |
|---|
| P/E (ttm): | 18.56 |
|---|
| EPS (ttm): | 3.94 |
|---|
| Div & Yield: | 2.53 (3.50%) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Positive Data on Novartis' JakaviZacks(Wed, 04:55 SGT)
- Positive Data on Incyte's JakafiZacks(Wed, 04:00 SGT)
- Ariad's Iclusig in GIST Phase II StudyZacks(Wed, 03:30 SGT)
- Big Pharma's Intellectual Property Bluesat Motley Fool(Tue, 18 Jun)
- Amarantus Teams With Becton, Dickinson For LymPro Development, Seeking PD-LID Candidateat Seeking Alpha(Tue, 18 Jun)
- PDL BioPharma wants arbitration in royalty disputeAP(Wed, 12 Jun)
- Questcor will pay at least $135M for Novartis drugAP(Tue, 11 Jun)
- Receptos rises as analysts start coverageAP(Tue, 4 Jun)
- Sector Snap: Analysts expect pharma restructuringAP(Tue, 28 May)
- Valeant to buy Bausch + Lomb for $8.7BAP(Tue, 28 May)
Key Statistics
| Forward P/E (1 yr): | 13.52 |
|---|
| P/S (ttm): | 3.12 |
|---|
| Ex-Dividend Date: | 26-Feb-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 5.10 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.29 |
|---|
| Mean Recommendation*: | 2.2 |
|---|
| PEG Ratio (5 yr expected): | 2.61 |
|---|
Business Summary
Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary...
View More